The Adult Hospital Level Standard Treatment Guidelines (STGs) and Essential Medicines List (EML) currently recommends the use of atazanavir and ritonavir (ATV/r) in patients with protease inhibitor (PI)-induced dyslipidaemia at high risk of developing cardiovascular disease. Darunavir and ritonavir (DRV/r) is a patient-specific medicine indicated for patients with documented PI resistance (i.e. for third line antiretroviral therapy). These two PIs are currently on tender as single agents (i.e. without ritonavir). Recently, the combination formulations ATV/r and DRV/r have been registered with the South African Health Products Regulatory Authority. Quotations have been supplied for provinces to procure these items (see Table 1 below). Utilisation of these products will reduce the pill burden on patients, which has been shown to be beneficial to patient adherence on anti-retrovirals (ARVs).